BR112023005002A2 - Geração de linhagem de células de ovário de hamster chinês recombinantes de alta produção para produção de proteína terapêutica - Google Patents

Geração de linhagem de células de ovário de hamster chinês recombinantes de alta produção para produção de proteína terapêutica

Info

Publication number
BR112023005002A2
BR112023005002A2 BR112023005002A BR112023005002A BR112023005002A2 BR 112023005002 A2 BR112023005002 A2 BR 112023005002A2 BR 112023005002 A BR112023005002 A BR 112023005002A BR 112023005002 A BR112023005002 A BR 112023005002A BR 112023005002 A2 BR112023005002 A2 BR 112023005002A2
Authority
BR
Brazil
Prior art keywords
yearing
chinese hamster
hamster ovary
therapeutic protein
ovary cells
Prior art date
Application number
BR112023005002A
Other languages
English (en)
Portuguese (pt)
Inventor
Louis DUMAS Bruno
Nabil LOUNIS Mohammed
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112023005002A2 publication Critical patent/BR112023005002A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/001—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y103/00—Oxidoreductases acting on the CH-CH group of donors (1.3)
    • C12Y103/05—Oxidoreductases acting on the CH-CH group of donors (1.3) with a quinone or related compound as acceptor (1.3.5)
    • C12Y103/05002—Dihydroorotate dehydrogenase (1.3.5.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/01—Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
    • C12Y603/01002—Glutamate-ammonia ligase (6.3.1.2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112023005002A 2020-09-21 2021-09-21 Geração de linhagem de células de ovário de hamster chinês recombinantes de alta produção para produção de proteína terapêutica BR112023005002A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20306068 2020-09-21
PCT/EP2021/075864 WO2022058603A1 (en) 2020-09-21 2021-09-21 Generation of a high producing recombinant chinese hamster ovary cell line for therapeutic protein production

Publications (1)

Publication Number Publication Date
BR112023005002A2 true BR112023005002A2 (pt) 2023-04-18

Family

ID=72840426

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023005002A BR112023005002A2 (pt) 2020-09-21 2021-09-21 Geração de linhagem de células de ovário de hamster chinês recombinantes de alta produção para produção de proteína terapêutica

Country Status (16)

Country Link
US (1) US20240043878A1 (cg-RX-API-DMAC7.html)
EP (2) EP4541812A3 (cg-RX-API-DMAC7.html)
JP (1) JP7901585B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230068401A (cg-RX-API-DMAC7.html)
CN (1) CN116457468A (cg-RX-API-DMAC7.html)
AU (1) AU2021342718A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023005002A2 (cg-RX-API-DMAC7.html)
CA (1) CA3195524A1 (cg-RX-API-DMAC7.html)
ES (1) ES3010648T3 (cg-RX-API-DMAC7.html)
HU (1) HUE070250T2 (cg-RX-API-DMAC7.html)
IL (1) IL301442A (cg-RX-API-DMAC7.html)
MX (1) MX2023003278A (cg-RX-API-DMAC7.html)
PL (1) PL4214308T3 (cg-RX-API-DMAC7.html)
TW (1) TWI912369B (cg-RX-API-DMAC7.html)
WO (1) WO2022058603A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202303597B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3134116A1 (en) * 2019-03-19 2020-09-24 Sanofi Cell lines and selection markers for protein production
TWI912369B (zh) * 2020-09-21 2026-01-21 法商賽諾菲公司 用於生產治療蛋白之高生產重組中國倉鼠卵巢細胞株之世代

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
KR100267720B1 (ko) 1997-12-29 2001-03-02 박호군 사람 글루타민 합성효소 유전자를 포함하는 발현벡터 및 이를 이용하여 동물세포에서 에리트로포이에틴을 고수율로 생산하는 방법
US20030166201A1 (en) * 2001-04-30 2003-09-04 Jensen Michael C. Selection systems for genetically modified cells
JP5756016B2 (ja) * 2008-10-29 2015-07-29 サンガモ バイオサイエンシーズ, インコーポレイテッド グルタミンシンセターゼ遺伝子の発現を不活性化する方法及び組成物
EP2674495A1 (en) 2012-06-14 2013-12-18 Sanofi CHO expression system
CA2965202C (en) * 2014-10-23 2023-02-28 Sanofi Novel selection marker for cell transfection and protein production
WO2020012446A1 (en) * 2018-07-13 2020-01-16 Enzene Biosciences Limited Double knock-out cho cell line method of its generation and producing therapeutic proteins therefrom
CN120174006A (zh) * 2018-07-13 2025-06-20 隆萨有限公司 用于通过降低内源性蛋白质的水平来改善生物产物的生产的方法
CA3134116A1 (en) * 2019-03-19 2020-09-24 Sanofi Cell lines and selection markers for protein production
EP3976799A4 (en) * 2019-05-31 2023-07-12 The Trustees Of Columbia University In The City Of New York MULTIPLICATION OF AN AUXOTROPHIC CELL LINE FOR THE PRODUCTION OF RECOMBINANT PROTEINS AND METHODS THEREOF
CN110343668B (zh) * 2019-07-23 2021-11-19 珠海联邦制药股份有限公司 一种敲除gs基因的cho细胞株及其制备方法与应用
TWI912369B (zh) * 2020-09-21 2026-01-21 法商賽諾菲公司 用於生產治療蛋白之高生產重組中國倉鼠卵巢細胞株之世代

Also Published As

Publication number Publication date
ES3010648T3 (en) 2025-04-04
ZA202303597B (en) 2024-08-28
MX2023003278A (es) 2023-04-12
TWI912369B (zh) 2026-01-21
EP4541812A2 (en) 2025-04-23
AU2021342718A1 (en) 2023-06-08
JP2023544267A (ja) 2023-10-23
EP4214308C0 (en) 2024-11-20
PL4214308T3 (pl) 2025-04-14
EP4214308B1 (en) 2024-11-20
EP4214308A1 (en) 2023-07-26
TW202227622A (zh) 2022-07-16
US20240043878A1 (en) 2024-02-08
KR20230068401A (ko) 2023-05-17
AU2021342718A9 (en) 2025-03-27
HUE070250T2 (hu) 2025-05-28
CA3195524A1 (en) 2022-03-24
CN116457468A (zh) 2023-07-18
WO2022058603A1 (en) 2022-03-24
EP4541812A3 (en) 2025-06-11
IL301442A (en) 2023-05-01
JP7901585B2 (ja) 2026-08-06

Similar Documents

Publication Publication Date Title
BR112018070250A2 (pt) linhagem celular para proteína recombinante e/ou produção de vetores virais
BR112022027096A2 (pt) Composições e métodos relacionados a agentes terapêuticos ativáveis
Chung et al. Fibroblast activation protein (FAP) is essential for the migration of bone marrow mesenchymal stem cells through RhoA activation
BR112021022666A2 (pt) Frações de separação e seus métodos e uso
BR112017008165B8 (pt) anticorpo de domínio único direcionado contra um componente intracelular e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
BR0114373A (pt) Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante
MX2021014007A (es) Proteinas de union a epcam y metodos de uso.
BR112016004095A2 (pt) administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores
BR112018006995A2 (pt) receptores anti-cd30 de antígeno quimérico
BR112014018679A2 (pt) variantes de albumina
BR112018071200A2 (pt) terapia genética para o tratamento da hemofilia a
BR112015018416A2 (pt) fórmulas à base de proteína hidrolisada e aminoácidos com um sistema de emulsão estável
WO2020061229A3 (en) Arc-based capsids and uses thereof
BR112023020920A2 (pt) Composição de hidrolisado de células de células cultivadas e aplicações da mesma
ZA202303597B (en) Generation of a high producing recombinant chinese hamster ovary cell line for therapeutic protein production
BR112021012240A2 (pt) Terapia de gene-célula-tronco hematopoiética para síndrome wiskott-aldrich
BR112021026789A2 (pt) Sialidases humanas recombinantes, proteínas de fusão de sialidase e métodos de uso das mesmas
BR112023003468A2 (pt) Variantes de uma xiloglucanase da família 44
Nakasato et al. A ubiquitin E3 ligase Efp is up-regulated by interferons and conjugated with ISG15
BR112022006923A2 (pt) Polipeptídeos recombinantes para localização celular regulável
BR112016014072A2 (pt) anticorpo isolado, sintético ou recombinante humano, ou uma parte funcional ou um equivalente funcional do mesmo, molécula de ácido nucleico isolado, sintético ou recombinante, vetor, célula isolada ou recombinante ou um animal não humano, composição, uso de um anticorpo ou parte funcional ou equivalente funcional, e, métodos para produzir um anticorpo ou parte funcional ou equivalente funcional, para detectar células mieloproliferativas ou linfoproliferativas, para determinar se uma célula mieloide ou célula linfoide é uma célula mieloproliferativa ou célula linfoproliferativa, para identificar células mieloproliferativas ou linfoproliferativas, para determinar se células mieloproliferativas ou linfoproliferativas estão presentes em uma amostra, para tratar e/ou prevenir um distúrbio mieloproliferativo ou linfoproliferativo, para determinar se um indivíduo sofre de um distúrbio mieloproliferativo ou linfoproliferativo, para tipificar uma amostra contendo célula mieloide ou uma amostra contendo célula linfoide de um indivíduo, e, para determinar se um paciente que sofre de um distúrbio mieloproliferativo ou distúrbio linfoproliferativo é um candidato para o tratamento com um anticorpo
BR112015025898A2 (pt) polipeptídeo, célula, ácido nucleico, vetor, vírus da varíola suína recombinante, composição, vacina, e uso de um peptídeo sinal
AR121961A1 (es) Inmunoterapia con citocina
BR112022007776A2 (pt) Composições e métodos para minimizar a perda de proteína em baixas concentrações de proteína
MX388883B (es) Mutaciones en proteinas del grupo hierro-azufre que mejoran la utilizacion de xilosa.